Haeseong Seong Park MD MPH

Oncology•Boston, MA

Gastrointestinal Cancer

Physician

Join to View Full Profile

450 Brookline AveBoston, MA 02215
Phone+1 617-632-4500
Fax+1 617-632-5370

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Investigational Cancer Therapeutics Fellowship In Early Drug Development, 2014 - 2015
Virginia Commonwealth University Health SystemFellowship, Hematology and Medical Oncology, 2011 - 2014
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2008 - 2011
Seoul National University College of MedicineClass of 2006

Certifications & Licensure

MA State Medical License 2022 - 2027
MO State Medical License 2015 - 2023
VA State Medical License 2008 - 2015
American Board of Internal Medicine Medical Oncology

Clinical Trials

Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma Start of enrollment: 2017 Nov 01
COMPLETED
PHASE2
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery Start of enrollment: 2018 Apr 20
Withdrawn
Phase 1, Phase 2
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer Start of enrollment: 2020 Jan 06
RECRUITING
PHASE1, PHASE2
Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors Start of enrollment: 2019 Dec 04
Active, not recruiting
Phase 1
Roles: Contact
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene Start of enrollment: 2022 Oct 05
RECRUITING
PHASE1
Roles: Principal Investigator, Contact
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Start of enrollment: 2019 Jul 22
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Sub-Investigator
Join now to see all

Publications & Presentations

PubMed

Chemical perturbations impacting histone acetylation govern colorectal cancer differentiation.
Pornlada Likasitwatanakul, Zhixin Li, Paul Doan, Sandor Spisak, Akhouri Kishore Raghawan
Gastroenterology. 2025-07-07
Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2gastric cancer.
Abbey Zidel, Alex Benton, Emma Brown, Shayla Shmuel, Alex Vanover
Scientific Reports. 2025-05-15
1 citations
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.
Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, Haeseong Park, Ding Wang
Clinical Cancer Research. 2024-12-16

Journal Articles

FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers
Haeseong Park, Andrea Wang-Gillam, Caron Rigden, Katrina S Pedersen, Nikolaos A Trikalinos, JAMA Oncology

Lectures

Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

FOLFIRINOX for the Treatment of Advanced Gastroesophageal CancersMay 2020